Psyence BioMed Becomes First Nasdaq Company to Produce GMP-Compliant Ibogaine HCl
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: Globenewswire
- Production Breakthrough: Psyence BioMed, through its investment in PsyLabs, becomes the first Nasdaq-listed company to successfully produce GMP-compliant high-purity ibogaine hydrochloride, marking a significant advancement in addressing unmet mental health needs.
- Quality Enhancement: The production of ibogaine HCl improves stability, solubility, and purity, aligning the compound with stringent medical and pharmaceutical development requirements, thereby enhancing the company's competitive edge in the biopharmaceutical industry.
- Strong Financial Position: With a cash balance of $12 million and no debt, alongside an ongoing Phase 2b psilocybin clinical trial, the company is well-positioned to support its strategic priorities moving forward.
- Board Changes: The appointment of Graham Patrick to the Board of Directors, with his extensive experience in cross-border transactions and corporate governance, is expected to provide valuable support for the company's international structure and compliance efforts.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on PBM
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Psyence BioMed Announces Share Consolidation Plan
- Share Consolidation Ratio: Psyence BioMed announced a 1-for-6.25 share consolidation effective February 2, 2026, aimed at increasing the stock price to enhance market appeal and investor interest.
- Shareholder Approval: At a special meeting on April 16, 2025, shareholders approved a consolidation authorization of up to 1-for-50, indicating strong support for the company's restructuring plans.
- Impact on Shares: Post-consolidation, the company will reduce its shares from 6,388,604 to 1,022,177, maintaining ownership percentages for shareholders while allowing for minor adjustments due to fractional shares.
- Exchange Agent Information: Continental Stock Transfer & Trust Company will act as the exchange agent for the consolidation, ensuring a smooth process for all shareholders and minimizing potential market disruptions.
Continue Reading
Psyence Biomedical (PBM) Announces 1-for-6.25 Reverse Stock Split Effective January 20, 2026
- Reverse Split Implementation: Psyence Biomedical has announced a 1-for-6.25 reverse stock split effective January 20, 2026, which will significantly reduce the outstanding shares from 6.38 million to 1,022,177, aiming to enhance share price and attract more investor interest.
- Shareholder Meeting Resolution: At a special meeting on April 16, 2025, shareholders approved a resolution allowing the board to implement a share consolidation of up to 1-for-50 before the next annual meeting, indicating strong support for optimizing the company's capital structure.
- Initial Split Authorization: The board initially authorized a 1-for-7.97 consolidation on May 5, 2025, reflecting the company's ongoing efforts to enhance market competitiveness and shareholder value through capital structure optimization.
- Subsequent Capital Adjustment: On December 4, 2025, the board approved a second consolidation at a ratio of 1-for-6.25, demonstrating the company's flexibility and ability to adapt to market changes in its capital structure.
Continue Reading